Figure 6. MeCP2 attenuates EPC functionality through autophagy. (A) FoxO3a, LC3 II, Beclin1, p62, ATG5, and ATG7 protein levels were detected by western blotting after GFP, Ad-MeCP2, Ad-MeCP2 + Rapa, Ad-sh-MeCP2, or Ad-sh-MeCP2 + CQ. (B) Cell migration was evaluated by Transwell migration assays after treatment for 48 h. (C) Cell adhesion ability was evaluated by matrix adhesion assays after treatment for 48 h. (D) Angiogenic ability was evaluated by Matrigel assays after treatment for 48 h. (E) Cell viability was evaluated with CCK-8 after treatment for 48 h. *P < 0.05, **P < 0.01, and ***P < 0.001 vs. control. #P < 0.05, ##P < 0.01, and ###P < 0.001 vs. Ad-MeCP2 treatment. φP < 0.05, φφP < 0.01, and φφφP < 0.001 vs. Ad-sh-MeCP2 treatment.